Why the study?
To provide theoretical insight into the development of Senecavirus A-related antivirals by reviewing the structural characteristics, enzymatic properties, and cleavage functions of its 3C protease.
This review provides theoretical insights into the structural and enzymatic properties of SVA 3Cpro to aid in the development of SVA-related antivirals.
Supports SVA 3Cpro as antiviral target; leaves open preclinical validation and clinical translation.
Senecavirus A (SVA) is an emerging virus, classified into the family Picornaviridae. It causes a severe vesicular disease in pigs. SVA 3C protein, a nonstructural protein, in itself is a protease (3Cpro), harboring the typical chymotrypsin-like fold with an S1 subsite. As a protease, 3Cpro plays a dual role in the replicative cycle of SVA. On the one hand, 3Cpro cleaves the viral polyprotein stepwise to generate different proteins. On the other hand, 3Cpro can specifically degrade a variety of host factors. The degradation of host factors may impair one or even more signaling pathways, making SVA not only efficiently propagate in cells but also ingeniously evade the host’s immune responses. Herein, we systematically reviewed SVA 3Cpro involved in its structural characteristics, enzymatic properties, and more importantly its functions in cleaving the viral polyprotein and host proteins, aiming to provide a theoretical insight into the development of SVA-related antivirals.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: